Pfizer’s $10.5B Deal With One of China’s Top Cancer Biotechs Is Another Sign the Game is Changing
Frank Vinluan / medcitynews - Pfizer unveiled a multi-drug R&D collaboration with Innovent Biologics, making it the latest big pharma company to reach a deal that taps into Chinese labs to source biotech innovation. This alliance will focus on developing next-generation drugs in the c…
AI Summary: Pfizer struck a $10.5 billion deal to acquire a leading Chinese oncology biotech, a transaction industry watchers say underlines China’s accelerating drug‑development muscle. Analysts flagged broader implications for global R&D competition, partnerships and where future oncology innovation — and manufacturing heft — might live.
DESTINY-Lung03: T-DXd Confirms Activity in HER2-Overexpressing NSCLC, but Triplet Therapy Falls Short
oncodaily - DESTINY-Lung03 Part 1 provides an important signal for the treatment of HER2-overexpressing non-small cell lung cancer (NSCLC). The study confirms that trastuzumab deruxtecan (T-DXd) monotherapy has clinically meaningful activity in […]
AI Summary: DESTINY‑Lung03 data confirmed trastuzumab deruxtecan has tangible activity in HER2‑overexpressing non‑small‑cell lung cancer, producing notable responses. Attempts to escalate to triplet regimens failed to add benefit, prompting a reality check on combination complexity and the need for sharper biomarkers rather than more drugs.
New Tool That Tracks How the Brain Removes Waste Could Offer Clues About Alzheimer’s
discovermagazine - Learn why understanding how the brain clears its waste could help researchers combat neurodegenerative diseases and age-related cognitive decline.
AI Summary: Researchers unveiled an imaging tool that tracks how the brain removes metabolic waste, mapping preferred drainage routes and pinpointing breakdowns associated with Alzheimer’s pathology. The technique could flag early clearance failure years before symptoms, offering potential biomarkers and therapeutic targets—because sometimes the answer to dementia is less about neurons and more about the plumbing.
Listen to the Latest ‘KFF Health News Minute’
kffhealthnews - The "KFF Health News Minute" brings original health care and health policy reporting from our newsroom to the airwaves each week.
AI Summary: A phase 2 study investigated FGFR inhibition with rogaratinib in succinate dehydrogenase–deficient gastrointestinal stromal tumors. Results reported tumor control in this rare molecular subset, offering a targeted therapeutic approach where options are sparse and validating FGFR as a biologic vulnerability in SDH‑deficient GIST.
MajesTEC-9 Results at ASCO 2026: Teclistamab Monotherapy Demonstrates Superiority Over PVd/Kd in Earlier-Line RRMM
oncodaily - At ASCO 2026, results from MajesTEC-9 (NCT05572515), the first phase 3 study of teclistamab monotherapy in patients with relapsed or refractory multiple myeloma (RRMM) after 1-3 prior lines of therapy, […]
AI Summary: Teclistamab monotherapy demonstrated superior progression-free survival and response rates versus pomalidomide‑based (PVd) and carfilzomib‑based (Kd) regimens in earlier-line relapsed/refractory multiple myeloma, showing durable remissions at 18 months. The data suggest a shift toward bispecific antibody therapy earlier in the treatment sequence for many patients.
FDA Approves Decnupaz (pivekimab sunirine-pvzy), the First ADC for Adults With BPDCN
oncodaily - On May 27, 2026, the U.S. FDA granted approval to pivekimab sunirine-pvzy (Decnupaz, AbbVie, Inc.), a CD123-directed antibody and alkylating agent conjugate, for the treatment of adults with blastic plasmacytoid […]
AI Summary: The FDA approved pivekimab sunirine (Decnupaz/pvzy), the first antibody‑drug conjugate for blastic plasmacytoid dendritic cell neoplasm (BPDCN), marking a regulatory win for an ultra‑rare blood cancer. The decision underscores ADCs’ growing role in niche hematologic malignancies and anchors AbbVie’s expanding ADC strategy.